Advancing Your Immuno-Oncology Pipeline

Understand the role of a CRO across all phases of immuno-oncology drug development

Steven Anderson PhD, Chief Scientific Officer

Covance immuno-oncology drug development timeline
Contact Us
icon-info-sheet

Info Sheet: Biopharma Solutions

left-img-info-sheet-biopharma-solutions

Maximizing asset value with solutions designed for biopharma

icon-immuno-oncology-expertise

Immuno-Oncology Expertise

left-img-capabilities

Discover our expertise in immuno-oncology drug development

icon-webinar-video

MarketPlace Video

Marketplace video
icon-case-study

Case Study: Flexibility for a Successful Partnership

Case study: Flexibility for a successful partnership

Rapidly establishing relevant models for preclinical oncology success

icon-white-paper

White Paper: Overcoming Immuno-Oncology Challenges

left-img-case-study-addressing-immunotherapy

Evidence-based approaches to address challenges in immuno-oncology

icon-white-paper

White Paper: Role of Biomarkers, Companion and Complementary Diagnostics

left-img-white-paper-complementary-diagnostics

Highlights of personalized medicine in immuno-oncology

icon-case-study

Case Study: End-to-end Drug and Diagnostic Development

Case study: End-to-end drug and diagnostic development

Support in immuno-oncology from preclinical design to approved product launch